Anat Polyachenko

Anat represents emerging to mature companies, as well as private equity and venture capital funds. She advises on a broad range of corporate and transactional affairs, including equity investments, cross-border mergers and acquisitions, licensing transactions, collaboration agreements, strategic alliances, and joint ventures.

Anat also advises pharma, biotech, and technology clients, and handles contractual arrangements for drug discovery, research, development, manufacturing, supply, and commercialization of new products.

Licensing and Collaboration Agreements

• Takeda in its co-development and co-commercialization license and collaboration with Protagonist for Rusfertide, an injectable hepcidin mimetic peptide in late-stage development for polycythemia vera.
• Astellas in its Research Collaboration and License Agreement with Elpiscience for novel bispecific macrophage engagers, including up to USD 37 million in upfront and option fees and potentially more than USD 1.7 billion in future development, regulatory, and commercial milestones.
• Astellas in its license agreement with 4D Molecular Therapeutics for the use of 4D's proprietary R100 vector for rare ophthalmic targets, including USD 20 million upfront and potential future option fees and milestones of up to USD 942.5 million.
• Astellas in its research collaboration and license agreement with PeptiDream to discover novel protein degraders for two targets selected by Astellas, with the option to select up to three additional targets.
• Pheon Therapeutics in its exclusive license agreement with Biocytogen Pharmaceuticals for the development and commercialization of antibody-drug conjugates (ADCs) developed using Biocytogen's proprietary RenMice™ platforms.
• Incyte in its collaboration with Biotheryx to discover and develop targeted protein degraders for novel oncology targets.
• GSK in its license agreement with WuXi Biologics for multiple novel bi- and multi-specific T cell engagers.
• Merck Sharp & Dohme in its collaboration and license agreement with PeptiDream Inc. for the discovery and development of novel peptide drug candidates, including the potential for up to USD 2.1 billion in regulatory, development and commercial milestones.
• CSL Seqirus in its collaboration and license agreement with Arcturus Therapeutics to access its late stage self-amplifying mRNA vaccine platform technology, including for COVID-19, influenza, and multi-pathogen pandemic preparedness.
• Vividion Therapeutics (a wholly owned and independently operated subsidiary of Bayer AG) in its strategic collaboration with Tavros Therapeutics to discover and enhance targeted oncology programs, including an upfront of USD 17.5 million, up to USD 430.5 million in milestone payments for four initial programs, and, if Vividion exercises its opt-in for up to five more targets, up to USD 482 million in additional payments.
• Astellas in its strategic research collaboration with FIMECS to discover protein degraders against multiple targets.
• H. Lundbeck A/S in its collaboration with Rgenta Therapeutics to discover small molecules targeting RNA regulation and splicing of disease-causing genes.
• Astellas in its license agreement with ExCellThera for the in vitro use of certain molecules in the field of pluripotent stem cells (PSCs) and PSC-derived cells.
• H. Lundbeck A/S in the licensing to Denovo Biopharma of global rights to idalopirdine (an oral 5-HT6 antagonist) for Alzheimer's Disease, schizophrenia and other indications, subject to options for Lundbeck to re-acquire such rights with the parties sharing China rights.

Mergers and Acquisitions

• Johnson & Johnson in connection with the spin-off of its consumer health business.
• Numab Therapeutics in the agreement with Johnson & Johnson to acquire Numab's subsidiary Yellow Jersey Therapeutics which holds its Phase 2-ready NM26 bispecific antibody program for atopic dermatitis for USD 1.25 billion.
• Abbot Laboratories in its strategic acquisition of Bigfoot Biomedical, Inc. This transaction will allow Abbott to further develop connected solutions for diabetes management.
• Bristol Myers Squibb (BMS) on the sale of its manufacturing facility in East Syracuse, New York to LOTTE.
• Bayer AG in its acquisition of drug discovery company Vividion Therapeutics for USD 1.5 billion upfront and up to USD 500 million in success-based milestone payments.
• Kite in the sale to BioNTech of their neoantigen TCR cell therapy R&D platform and manufacturing facility.

• Certified Information Privacy Professional US Private Sector (CIPP/US)
• New York State Bar Association - Member
• Israel Bar Association - Member
• Licensing Executives Society (LSE) USA & Canada - Member